In vitro/in vivo correlation a b s t r a c t
Introduction
Compared to the gastro-intestinal tract, kidney, liver or brain, the expression and functionality of drug transporters remain poorly characterised in the lung, which renders pulmonary drug absorption data challenging to interpret [1, 2] . Since the epithelium is the major permeability barrier in the lung, in vitro respiratory epithelial cell culture models have been employed to enhance understanding of the role of active transport mechanisms in the disposition of inhaled drugs [1, 3] . In absence of a convenient and truly representative model of the alveolar epithelium, bronchial systems have been favoured [3, 4] . Among these, the human bronchial cell line Calu-3 and normal human bronchial epithelial (NHBE) cells are gaining in popularity due to their capacity to develop polarised cell layers morphologically similar to the native epithelium and suitability for permeability measurements when cultured at an air-liquid interface (ALI) [4] [5] [6] . However, although the presence of active drug transport mechanisms has been confirmed in Calu-3 and NHBE layers [1, [6] [7] [8] [9] , an overview of the range of transporters being expressed and functional in these models is still lacking.
P-glycoprotein/multidrug resistance protein 1 (P-gp/MDR1) is a member of the ATP-binding cassette (ABC) efflux transporter family and plays a major role in drug-drug interactions [10] , limitation of oral drug absorption and poor drug penetration in the central nervous system [11] . As it has been reported several drugs administered by the pulmonary route might be MDR1 substrates [1] , targeting the transporter present in the epithelium has been envisaged as a strategy to increase the residence time of inhaled drugs in the lung tissue. Consequently, MDR1 is by far the most extensively studied drug transporter in the lung [1] . Although weakly expressed in the lung as compared to other major organs [12] , the presence of the MDR1 protein has been demonstrated in the bronchial epithelium [1] . However, its actual impact on the pulmonary absorption of established substrates is a matter of debate [1] . Similarly, reports on the expression, localisation and functionality of MDR1 in bronchial epithelial cell culture models are conflicting [1] . Passage number and time in culture have recently been shown to impact on MDR1 expression or activity in ALI bronchial epithelial layers [6, 13, 14] , which may partly explain discrepancies between studies.
Identifying the transporter protein involved in carrier-mediated drug trafficking is highly challenging in biological systems expressing multiple transporters with broad and overlapping substrate specificities. For instance, the cardiac glycoside digoxin has been well characterised as an MDR1 substrate and is largely used for evaluating the risk of drug-drug interactions with new chemical entities consequent to their modulation of MDR1 activity [15, 16] . Accordingly, although not an inhaled drug, digoxin has been used for probing MDR1 activity in bronchial cell culture models [13] and in rodent lungs [13, 17] . However, digoxin has also been described as a substrate for carriers other than MDR1. These belong to both families of ABC efflux pumps and organic anion transporting polypeptide uptake transporters (OATP; gene symbol: SLCO), namely MDR3 [18] ; OATP1B3 [19] and OATP4C1 [20, 21] . Conversely, more recent studies have shown OATP1B3, as well as OAT-P1A2, OATP1B1 and OATP2B1, do not transport digoxin [22, 23] . In addition, it is now largely acknowledged that chemical inhibitors commonly used in functional or mechanistic studies, including those originally thought to be specific, actually interact with multiple transporters [24, 25] .
In this context, our aim was to characterise the bidirectional transport of digoxin in ALI bronchial epithelial cell layers in order to evaluate the contribution of the MDR1 efflux pump and thus the reliability of the drug as a MDR1 probe in such models. To assist in the analysis of in vitro permeability data, the expression of a range of transporter genes was initially profiled in the cell culture models. After confirmation of the presence of the MDR1 protein in bronchial epithelial cell layers, the impact of a panel of chemical, immunobiological and metabolic inhibitors on digoxin apparent efflux was investigated in an attempt to identify the transporter involved. Layers of Madin-Darby canine kidney epithelial (MDCKII) cells transfected with the human MDR1 transporter and their wild type counterparts were used for comparison throughout the study.
Materials and methods

Cell culture
Unless otherwise stated, all reagents were purchased from Sigma-Aldrich, UK. The human cancerous bronchial epithelial cell line Calu-3 was obtained from the ATCC (Rockville, MD, USA) and used at a 'low' (25) (26) (27) (28) (29) (30) or 'high' (45-50) passage number. Cells were maintained as previously described [13] . For experiments, they were seeded at a density of 1 Â 10 5 cells/cm 2 on 12 well 0.4 lm pore size polyester Transwell Ò cell culture supports (Corning Costar, High Wycombe, UK). Cells were raised to the air-liquid interface (ALI) after 24 h and maintained on filters for 21 days prior to experimentation.
Normal human bronchial epithelial (NHBE) cells (Lonza, Slough, UK) were cultured using the Lonza proprietary B-ALI Ò kit according to the manufacturer's instructions. Cells at passage number 2 were seeded at a density of 1. The medium was replaced on the following day, and after 72 h, cells were raised to the ALI. The medium was thereafter changed every 2-3 days, and cell layers were used after 21 days at the ALI. The human cancerous colonic epithelial cell line Caco-2 and the human embryonic kidney HEK293 cell line were obtained from the ATCC. Wild type and MDR1 transfected Madin-Darby Canine Kidney (MDCKII-WT and MDCKII-MDR1) cells were purchased from the Netherlands Cancer Institute (NKI-AVL, Amsterdam, Netherlands). All cells were cultured in DMEM supplemented with 10% % v/v foetal bovine serum, 100 IU/ml penicillin-100 lg/ml streptomycin solution, 2 mM L-glutamine and 1% v/v non-essential amino acids. Cells were seeded at a density of 2 Â 10 5 cells/cm 2 on 12 well polyester Transwell Ò cell culture supports and cultured under submerged conditions for 5 (HEK293, MDCKII) or 21 (Caco-2) days.
Gene expression analysis
Calu-3 and NHBE cell layers were harvested from Transwell Ò inserts on the same day as 3 H-digoxin permeability experiments. mRNA isolation and cDNA synthesis were performed as described previously [26] .
Manual TaqMan Ò analysis of the ABCC7 and ABCC10-12 genes was performed in triplicate in a 25 ll reaction mixture containing 30 ng cDNA, TaqMan Ò Universal PCR Master Mix (containing AmpliTaq Gold DNA polymerase, dNTPs with dUTP, passive reference and optimised buffer) and Assay-on-demand™ gene expression assay mix (containing 18 lM random hexamer primers). All other genes investigated were analysed via automated Taqman Ò PCR low density arrays using custom designed 384-well cards as described previously [26] . Amplification curves were analysed using the SDS2.1 software (Applied Biosystems, Foster City, CA) and thresholds for generation of C T data were calculated automatically by the software. Target genes were compared with the two housekeeping genes RPLP0 (Large Ribosomal Protein) and MVP (Major Vault Protein) DC T and assigned arbitrary categories for relative gene expression levels based on the 2 ÀDC T value, i.e. relative expression levels >0.5 were considered as 'high' (+++), 0.02-0.5 as 'moderate' (++), 0.001-0.02 as 'low' (+) and <0.001 as 'negligible' (À).
Western blotting
Cells were detached from the surface of the filters/flasks by the addition of 500 ll non-enzymatic cell dissociation buffer prepared in HBSS without calcium and magnesium salts. Cells were counted and resuspended in RIPA cell lysis buffer containing 1 ll of protease inhibitor cocktail set II per 200 ll (ratio of 20 million cells per 1 ml buffer solution) and agitated at 700 rpm at 4°C for 30 min. Cell debris was pelleted at room temperature by centrifugation at 12,000g for 20 min and the resulting supernatant decanted. Protein concentration was quantified using the RC DC™ protein assay (BioRad, Hemel Hempstead, Hertfordshire).
Protein samples were resolved using 7% Tris-acrylamide gels. Transfer to a nitrocellulose membrane was conducted for 60 min at 100 V and at a temperature of 4°C. Proteins transferred onto Western blots were visualised by staining with copper phthalocyanine 3,4 0 ,4 00 ,4 00 0 -tetrasulphonic acid tetrasodium salt (CPTA). Samples were probed for the presence of MDR1 protein using 5 lg/ml of the mouse anti P-glycoprotein C219 primary antibody (Calbiochem, Nottingham, UK) for 16 h at 4°C. All steps were performed using a chemiluminescence detection kit according to the manufacturer's instructions (Invitrogen, Paisley, UK).
Immunohistochemistry
Cell layers were probed for MDR1 protein expression on the same day as functional experiments. Cell layers were rinsed twice with PBS before being fixed with 3.7% w/v paraformaldehyde for 15 min. Fixed cell layers were permeabilised using 0.1% v/v Triton X-100 in PBS for 5 min and rinsed in PBS. Samples were blocked for 30 min with 1% w/v bovine serum albumin (BSA) in PBS to prevent non-specific binding, followed by incubation with the primary mouse anti-human MDR1 antibodies: 15 lg/ml MRK16 (Abnova, Newmarket, UK) or 20 lg/ml UIC2 (Enzo Life Sciences, Exeter, UK) in blocking solution for 60 min at 37°C. Cells were washed in 1% w/v BSA in PBS to remove unbound primary antibody before incubation with a solution of the secondary FITC-labelled goat antimouse IgG (1:64) in PBS, for a further 30 min. Cell nuclei were counter-stained with propidium iodide (PI) 1 lg/ml in PBS for 30 s. Inserts were washed with PBS before the filter was excised and mounted on a slide using DABCO anti-fade mounting media. Samples were imaged by a Meta 510 confocal microscope (Zeiss, Welwyn Garden City, UK), excited at 485 nm and 543 nm wavelengths and emission observed at 519 nm and 617 nm for FITC and PI, respectively. Z-stack reconstructions of samples were the average of four images for every 0.5 lm slice through the sample.
Flow cytometry
On the day of containing FITC-labelled goat anti-mouse IgG (1:1000) and incubated at 4°C for 30 min. After two PBS wash steps to remove any unbound secondary antibody, samples were fixed by the addition of 500 ll fixing solution (0.5% v/v formaldehyde in PBS) and stored at 4°C in the dark for up to 1 week before analysis. An unstained sample and the appropriate isotype controls were included in each analysis to address autofluorescence and non-specific binding, respectively.
For data analysis, each sample population was gated to only include cells of interest based on either their forward scatter (cell size) and/or side scatter (cell granularity) profiles. Dead cells were identified from optimisation experiments with PI and excluded from the analysis. A total of 30,000 events were collected for each sample. Raw data were analysed using WinMDI 2.9 software (build #2, 6-19-2000; Scripps Research Institute: http://facs.scripps.edu/ software.html) and the mean fluorescence intensity (MFI) value was determined as MFI = [MFI value for sample] À [MFI value for isotype/unstained sample] for each marker.
The UIC2 shift assay was performed as described previously [27] . Samples were treated as outlined above, but first incubated at room temperature for 10 min either alone in 0.5% v/v FBS in PBS or in presence of the chemical inhibitors PSC833 (1 lM) or MK571 (30 lM), before the addition of the UIC2 primary antibody (2 lg/ml). The relative MFI was calculated as the ratio between the MFI of the sample (treated with inhibitor) against the MFI of the cells alone.
Transport studies
Permeability experiments were conducted using 25 nM 3 H-digoxin (Perkin Elmer, Cambridge, UK) in 5 day (MDCKII cells) or 21 day (Calu-3 and NHBE cells) old cell layers in the apical to basolateral (AB) and basolateral to apical (BA) directions in quadruplicate.
14 C-mannitol (6.55 lM, Perkin Elmer) was used in all experiments as a marker of epithelial barrier integrity. Cell layers were allowed to equilibrate at 37°C for 60 min in standard buffer solution (SBS) comprising HBSS supplemented with 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 1% v/v dimethyl sulfoxide (DMSO) in presence or absence of the inhibitors PSC833 (1 lM), MK571 (30 lM) or sodium azide (15 mM). Transepithelial electrical resistance (TEER) measurements were taken using an EVOMmeter with chopstick electrodes (World Precision Instruments, Stevenage, UK) and only bronchial epithelial cell layers with a TEER > 300 X cm 2 were accepted for experiments. Permeability studies were then carried out as previously detailed [13] maintaining the concentration of substrate, paracellular marker and inhibitors constant throughout the experiments. Cells were maintained at 37°C and rotated at 60 rpm on an orbital shaker with the exception of temperature dependent studies where the samples were maintained at 4°C. For biochemical inhibition assays, cell layers were first incubated in SBS containing the mouse anti-human MDR1 antibodies (20 lg/ml UIC2 or 15 lg/ml MRK16) for 60 min at 37°. This was then removed prior to conducting the transport experiments as outlined above. The TEER was measured again at the end of the transport studies to verify the integrity of the cell layers. All samples were mixed with 2 ml OptiPhase HiSafe 2 scintillation cocktail (Perkin Elmer, Cambridge, UK) and counted using a Wallac 1490 liquid scintillation counter (Wallac, Turku, Finland). Apparent permeability coefficients (P app ) were calculated using the following equation:
where dQ/dt is the flux of the substrate across the cell layer, A is the surface area of the filter and C 0 is the initial concentration of the substrate in the donor solution.
Cell layers with 14 C-mannitol P app values >1.5 Â 10 À6 cm/s were excluded from the analysis. Efflux ratios were calculated as the ratio of the secretory (BA)/absorptive (AB) apparent permeability (P app ) values.
ATP depletion assay
Calu-3 and MDCKII cell layers were incubated for 3 h in either SBS alone or in SBS containing 15 mM sodium azide. No significant reduction in TEER values was observed at the end of the exposure time. Cells were then assayed for ATP content using the ATP-lite Ò kit (Perkin Elmer) according to the manufacturer's instructions with minor amendments. In brief, cells were lysed using 50 ll cell lysis buffer at room temperature on an orbital shaker set at 700 rpm. After 5 min, 100 ll luminescent substrate buffer was added and samples were incubated for a further 5 min at 700 rpm. Samples were then transferred to a black 96 well plate, dark adapted for 10 min and analysed for luminescence. ATP content was expressed as the average % relative to the control (SBS alone; n = 3 layers).
Statistics
Results for permeability data were expressed as mean ± standard deviation. Initial data sets with n P 5 were assessed for normality and the data were shown to fit a normal (Gaussian) distribution. Therefore, normality was assumed for all data sets presented in this study. These were compared using a two-tailed, unpaired Student's t-test with Welch correction applied (to allow for unequal variance between data sets). Statistical significance was evaluated at 99% (p < 0.01) and 95% (p < 0.05) confidence intervals. Data considered to be statistically significantly different from control conditions are represented with ÃÃ or Ã , respectively. All statistical tests were performed using GraphPad InStat Ò version 3.06.
Results
Transporter gene expression
Recently, the expression of a panel of drug transporters has been mapped by semi-quantitative reverse transcriptase polymerase chain reaction in human airway epithelial cells grown under submerged conditions on tissue culture plates [28] . Comparatively, a quantitative analysis of transporter expression in respiratory cell culture absorption models is currently lacking, whereas this would aid the interpretation of in vitro pulmonary permeability data. Hence, we evaluated the expression of selected drug transporter genes in 21 day old ALI Calu-3 layers at a low (25) (26) (27) (28) (29) (30) (Table 1 ). When differences in transporter expression were obtained between the in vitro models investigated, these were restricted to one arbitrary category (as defined in the method section). This reveals that, despite being of cancerous origin, Calu-3 layers appear to be a suitable in vitro model in which to investigate broncho-epithelial drug transporters. However, it is noteworthy that ABCB1 (MDR1) expression levels were inconsistent between the three cell culture systems studied. Indeed, they were determined as negligible in NHBE cells, low in Calu-3 cells at a high passage and moderate in low passage Calu-3 layers (Table 1) .
MDR1 protein expression
Three different protein detection techniques and a panel of MDR1 antibodies were employed to confirm the presence of MDR1 in bronchial in vitro permeability models.
Western blotting with the C219 antibody detected a protein band at $170 kDa for the two positive controls Caco-2 and MDCKII-MDR1 cells which was absent for the negative control cell lines HEK293 and MDCKII-WT (Fig. 1) . In comparison, protein bands were observed at $150 kDa for all Calu-3 cell lysates and were the strongest for cells at a high passage number cultured at the ALI (Fig. 1) .
The mouse anti-human MDR1 antibodies UIC2 and MRK16 were subsequently used for immunohistochemistry and flow cytometry. A positive immunohistochemical signal was obtained with both antibodies on the apical membranes of all but HEK293 cell layers investigated (Fig. 2) . This was however discontinuous on NHBE and low passage Calu-3 layers (Fig. 2) . Both MDCKII-WT and MDCKII-MDR1 cell layers stained positively, possibly due to the cross-reactivity of the antibodies with the canine mdr1 expressed in the cells [29] . Staining appeared nevertheless more intense for the transfected cells.
Flow cytometry using the UIC2 antibody produced a low MFI value of 1.3 with the negative control MDCKII-WT cells, whereas the MDCKII-MDR1 positive cell control generated a MFI value of 7.5, demonstrating the UIC2 antibody reacts specifically with MDR1. At low passage, 36% of Calu-3 cells were shown to express the MDR1 transporter in comparison with 70% at a high passage, 
Signal intensity represented as: À (<0.001) 'negligible expression'; + (0.001-0.02) 'low expression', ++ (0.02-0.5) 'moderate expression, +++ (>0.5) 'high expression as compared to the two house-keeping genes RPLP0 and MVP.
resulting in a MFI of 5.2 and 15.0, respectively (Fig. 3) . In contrast, only 6% of NHBE cells expressed MDR1 (MFI = 1.3). Similar trends in MDR1 expression levels were obtained with the MRK16 antibody with, however, lower fluorescence values recorded, likely due to a weaker affinity of this antibody for MDR1 ( Fig. S1 ; Supplementary information).
MDR1 functionality
The well-established MDR1 substrate digoxin is often used to probe MDR1 in biological systems, both in vitro and in vivo [13, 17] . However, the drug has also been reported to be a substrate for other transporters detected at the gene level in our bronchoepithelial cell layers (e.g. some of the OATP) [20, 21] . Hence, in order to verify the functionality of MDR1 in bronchial epithelial cells, we performed an UIC2 antibody shift assay in presence of the potent MDR1 inhibitor PSC833 as an alternative to measuring digoxin efflux ratios. This assay is based on the observation that binding of MDR1 ligands alters the conformation of the transporter, which increases the affinity of the UIC2 antibody for the MDR1 protein and causes a shift in fluorescence intensity [30, 31] . Relative MFI values of 1.8 and 1.06 were obtained when MDCKII-MDR1or MDCKII-WT cells, respectively, were pre-incubated with PSC833, in line with their role as positive and negative controls ( Fig. S2; Supplementary  information) . Values of 1.27 and 1.26 were calculated for Calu-3 cells at a low or high passage, respectively, while NHBE cells produced a relative MFI of 1.16 ( Fig. S2; Supplementary information), indicating the presence of a MDR1 activity in bronchial epithelial cells.
3.4.
3 H-digoxin bidirectional transport 3 H-digoxin permeability measurements were performed in both absorptive (AB) and secretory (BA) directions in MDCKII, Calu-3 and NHBE cell layers.
Both MDCKII-WT and MDCKII-MDR1 cell layers displayed a net secretory transport of 3 H-digoxin (Fig. 4) which was significantly reduced (p < 0.01) at 4°C ( Fig. S3; Supplementary information) .
The presence of an apparent efflux mechanism in the two cell types was allegedly ascribed to the activity of the canine mdr1 transporter in MDCKII cells [29] . As predicted, 3 H-digoxin efflux ratio was significantly higher (p < 0.01) in transfected cells (Fig. 4) , reflecting the involvement of the human MDR1 transporter in 3 H-digoxin asymmetric transport in the cell line.
A large degree of variability in 3 H-digoxin permeability values was observed between the two batches of NHBE cells employed, despite originating from the same donor (Fig. 4) . Accordingly, a range of efflux ratios between 1.0 and 2.3 were calculated for the two batches tested under identical culture conditions, questioning the presence of an efflux mechanism for digoxin in NHBE layers. Although within the acceptable range, 14 C-mannitol BA permeability values were significantly different (p < 0.05) between the two batches, which might have contributed to the variations in 3 H-digoxin secretory transport obtained. Net secretory transport of 3 H-digoxin was observed in both low and high passage Calu-3 layers, but with a higher efflux ratio measured at a low passage number (Fig. 4) . 3 H-digoxin asymmetric transport was abolished at 4°C ( Fig. S3 ; Supplementary information), confirming the involvement of a transporter-mediated mechanism.
Impact of inhibitors on 3 H-digoxin bidirectional transport
In order to evaluate the contribution of MDR1 to digoxin trafficking in MDCKII and Calu-3 layers, inhibition studies were performed with PSC833 (1 lM), the two specific MDR1 inhibitory antibodies UIC2 (20 lg/ml) and MRK16 (15 lg/ml) as well as MK571 (30 lM), an inhibitor of the multidrug resistance proteins (MRP) [32] which had previously been reported not to inhibit MDR1 even at a higher concentration of 50 lM [33] . Considering the poor reproducibility of transport data in NHBE layers, inhibition studies were not performed in this model. (Table 2 ). This suggested an involvement of MDR1/mdr1 in the drug transport in both cell lines. Nevertheless, this was not confirmed by functional inhibitory studies with the UIC2 and MRK16 antibodies.
Both antibodies are MDR1 specific probes that react with extracellular loops of the transporter, fixing it in a conformational state and thus altering the binding of its substrates [30, 31] . As anticipated, the antibodies had no significant impact on 3 H-digoxin trafficking in MDCKII-WT cells, but significantly decreased 3 H-digoxin BA P app in MDCKII-MDR1 layers ( Table 2) . None of the antibodies affected 3 H-digoxin permeability in Calu-3 cells at a high passage number (Table 2) . A small but statistically significant decrease in BA 3 H-digoxin transport was observed in Calu-3 layers at a low passage number with the MRK16 antibody, whereas the UIC2 clone had no impact on the drug secretory transport in these layers (Table 2).  MK571 enhanced   3 H-digoxin absorptive transport in all cell types but only reduced the drug secretory permeability in Calu-3 cell layers (Table 2) . A relative MFI of 1.05 was obtained in an UIC2 antibody shift assay performed in MDCKII-MDR1 cells incubated with MK571, confirming the compound does not bind to MDR1.
Impact of ATP depletion on 3 H-digoxin bidirectional transport
Since ABC transporters are ATP-dependent, the effect of a reduction of ATP cellular levels on 3 H-digoxin P app in MDCKII and Calu-3 layers was finally assessed. Incubation with 15 mM sodium azide for 3 h induced a $70-80% and $50% ATP depletion in MDCKII or Calu-3 layers, respectively (Table 3) . Interestingly, no significant effect of the metabolic inhibitor on digoxin permeability was observed in MDCKII-WT (Table 4), which is in contradiction with a presumed role of the canine mdr1 in the drug apparent efflux in the cell culture model. In contrast, decreased ATP production in MDCKII-MDR1 resulted in an enhanced or reduced digoxin transport in the absorptive or secretory directions, respectively (Table 4) . Moreover, in these conditions, BA transport was not significantly different (p > 0.05) from that in the wild type cell layers, suggesting complete inhibition of the MDR1 transporter. Reduction in ATP levels in Calu-3 layers did not affect 3 H-digoxin apparent efflux at a low passage number but decreased the BA transport by $10% at a higher passage number (Table 4 ).
Discussion
Due to the complexity of the lungs, ALI human bronchial epithelial cell layers are becoming popular systems for investigating drug-transporter interactions in the airway epithelium [1, 7] . However, the expression and functionality of most transporters have yet to be meticulously characterised in these models. In particular, the presence and activity of the MDR1 efflux pump in NHBE and Calu-3 layers remain controversial to date [1] . This may be explained by inter-laboratory variations in culture conditions but equally attributed to the use of non-specific substrates and inhibitors in functional studies.
This study characterised MDR1 expression and the bidirectional transport of the MDR1 probe digoxin in layers of NHBE and the Calu-3 cell line at low (25) (26) (27) (28) (29) (30) or high (45-50) passage numbers using MDCKII-MDR1 and wild type equivalents for comparison.
MDR1 expression data obtained by three independent protein detection techniques using three different MDR1 antibodies were in agreement and indicated a weak presence of the transporter in NHBE cells as well as an increased expression at a high passage number in Calu-3 cells (Figs. 1-3) . Surprisingly, protein expression levels in the cell line were in contradiction with the higher ABCB1 transcript levels measured at an early passage number (Table 1) . This highlights the importance of investigating transporter expression at the protein level in complement to gene profiling for a reliable appraisal of their presence in the cell culture system under investigation as well as unbiased interpretation of functional data. Western blotting revealed a protein band for Calu-3 samples at a molecular weight $20 kDa lower than for Caco-2 and Table 2 Impact of inhibitors on Data are presented as mean ± SD (n = 3 layers). MDCKII-MDR1 cells (Fig. 1 ). Hamilton and colleagues [34] also obtained a band $150 kDa in Calu-3 cells using the same C219 antibody. This clone is known to react with MDR3 ($150 kDa) as well as with MDR1. However, no ABCB4 (MDR3) transcripts were detected in the cell line (Table 1) , in agreement with the absence of this transporter in human airway epithelium samples [35] . More plausible causes for the presence of a band at a molecular weight lower than expected could include impaired post-translational modifications such as a different degree of glycosylation in Calu-3 cells. The impact of glycosylation on MDR1functionality is not completely understood to date with studies having reported either an uncompromised efflux activity [36, 37] or conversely, a diminished function [38, 39] of the non-glycosylated transporter. It had also been postulated that glycosylation was crucial for correct folding of the MDR1 protein into the cell membrane [40] . However, a shift assay performed with the conformation sensitive IUC2 antibody on Calu-3 cells demonstrated that the efflux pump expressed in the cell line was capable of binding the PSC833 inhibitor and modifying its conformation following ligand recognition (Fig. S2 , Supplementary info) similarly to a non-glycosylated MDR1 mutant in presence of the inhibitor cyclosporin A [36] . This indicated that, despite a possible altered structure, MDR1 was functional in the Calu-3 cell line. The 3 H-digoxin apparent efflux ratio measured in NHBE layers was poorly reproducible and was therefore not investigated further (Fig. 4) . In Calu-3 layers, this was higher at a low passage (Fig. 4) whereas MDR1 protein expression levels were greater in cells at a high passage number (Figs. 1-3) . 3 H-digoxin transport was not affected by ATP depletion at low passage and only marginally at a high passage number (Table 4) . Furthermore, the two MDR1 specific inhibitory antibodies MRK16 and IUC2 had no impact on the drug trafficking in high passage Calu-3 layers while the MRK16 clone alone decreased BA transport at a low passage number (Table 2). The extent of MDR1 inhibition by MRK16 and UIC2, although specific, has been described as partial (10-40%) and largely dependent on the substrate under investigation [41] . Assuming that the 3 H-digoxin permeability in the secretory direction in MDCKII-MDR1 cells above that in their wild type counterparts is the component mediated by the transfected human efflux pump, a $20% and $30% reduction in MDR1 mediated digoxin transport was obtained with the UIC2 and MRK16 antibodies, respectively, which validated the experimental protocol followed. Finally, MK571 increased 3 H-digoxin absorptive transport in both MDCKII and Calu-3 layers but only reduced its secretory transport in the bronchial cell line (Table 2 ). In contrast, the drug permeability in the BA direction was decreased in presence of PSC833 in all cell layers (Table 2 ). In addition to its inhibitory properties on various MRP carriers [32] , MK571 has been recently reported to interfere with the activity of OATP1B3 and OATP2B1 at a concentration as low as 1 lM [42, 43] . Its modulatory effects on other OATP transporters present in Calu-3 layers (Table 1) are currently unknown. Nevertheless, the compound has been shown not to interact with MDR1 [33] , which we confirmed in an IUC2 shift assay. Although PSC833 was originally developed as a specific MDR1 inhibitor, it has since been reported to inhibit other ABC transporters, such as the bile salt extrusion pump (BSEP) [44] , MRP2 [45] or the breast cancer resistance protein (BCRP, Solvo Biotech website) and its ability to inhibit OATP transporters has been suggested [46] . Taken together, 3 H-digoxin permeability data in Calu-3 layers do not support an exclusive participation of the MDR1 transporter in its apparent efflux and suggest the involvement of one or several ATP-independent transport system(s). Similarly, it has previously been demonstrated that MDR1 was not the sole transporter responsible for digoxin asymmetric transport in the Caco-2 intestinal absorption model [33] and in MDR1 transfected MDCK cell layers [47] .
Although this/these transporter(s) remain(s) to be identified, OATP4C1 might be a possible candidate since digoxin is a known substrate [20, 21] , the transporter is present in Calu-3 layers and a lower gene expression was observed at a high passage number (Table 1) . Assuming protein levels are in agreement with those of mRNA transcripts, this could explain the reduced digoxin apparent efflux in high passage cell layers. This assumption implies a basolateral location of OATP4C1 in Calu-3 layers in line with the basolateral presence of OATP transporters that has been recently postulated in the airway epithelium of foals [48] . However, there remains a possibility that digoxin is transported across bronchial epithelial cell layers by a transporter yet to be characterised, as suggested in other cell culture models [22, 23, 47] . For instance, in addition to the apical MDR1 efflux pump, a basolaterally located uptake transporter was required to account for digoxin net secretory transport in MDCKII-MDR1 cell layers but this transporter could not be identified using a panel of inhibitors [47] . As previously debated for the MDCKII-MDR1 absorption model [47] , the likely involvement of multiple transporters in digoxin bidirectional transport in Calu-3 layers questions its suitability for probing MDR1 activity in the bronchial epithelium.
Conclusions
This study exemplifies the complexity of analysing in vitro permeability data obtained with substrates of multiple transporters and highlights the need for thorough characterisation of transporter expression in cell based drug absorption models. The sole participation of MDR1 in digoxin net secretory transport in Calu-3 layers could not be demonstrated and the contribution of an ATP-independent transporter such as a basolaterally located member of the OATP family was therefore hypothesised. Identification of this unknown transporter might provide a better understanding of the distribution of drugs in the pulmonary tissue.
